The Ministry of Health has reported this Thursday that in Spain 25,745,178 doses have been administered, which allows that, as of this Tuesday, almost 17.5 million citizens (17,487,591, 36.9% of the population) have at least one dose of the covid-19 vaccine. While the percentage of the population that has the full agenda ascends to 18,2% (that is, 8,614,678 people).
In addition, the 51.5% of Spaniards aged 50 to 59 have already inoculated at least one dose of the vaccine, just over two weeks after the vaccination process of this age group became general in all the autonomous communities.
The Health report on the vaccination campaign also details that the complete guideline has been 9.1% inoculated of this group.
The vaccination campaign of this group, which is immunized with the preparations of Pfizer, Moderna and Janssen, began at the end of the first week of May in the Community of Madrid and the Region of Murcia, and was generalized in the rest of the communities in the following week.
It is a large group of the population – the so-called baby-boom generation-, whose census to be vaccinated amounts to 7,033,306 people, according to the Ministry of Health. The generation of 50 to 59 began to be vaccinated in a generalized way when the immunization of the population group most vulnerable to the coronavirus, those over 60 years old, had already been advanced.
Janssen for the 40 to 49 year old?
The next group to be vaccinated will be people from 40 to 49 years (born between 1972 and 1981, both inclusive), for which according to the last update of the vaccination strategy “Vaccines considered based on availability, the context of the pandemic will be used and of the evidences “.
This past Tuesday, the Public Health Commission, in which all the Autonomous Communities are represented, stressed that “the main priority at this time is extend vaccination in an agile way by age groups to ensure that all people are vaccinated in the shortest possible time. ”
For this, the Ministry of Health is exploring the possibility of vaccinating with Janssen to the age group between 49 and 40 years of age. This matter was discussed in the Interterritorial Council from the National Health System on Wednesday but a firm decision was not reached. Health continues to study this alternative, since it considers that there is time before this age group begins to be inoculated in the first half of June.
One of the main advantages of this vaccine is that it is a single dose, single dose, so that people vaccinated with this serum could plan their holidays regardless of the time interval in which they would have to return to their usual places of residence to receive the second dose.
The Janssen vaccine has been the subject of controversy after the suspension of the pricks by the US after detecting rare cases of cases in women. In Europe, European Medicines Agency (EMA) has given the go-ahead for inoculation by stating that the benefits of the vaccine outweigh its risks.
Rest of groups
Regarding the older age groups, the Ministry of Health reported this Thursday that almost 100 percent of Spaniards over 80 years of age already have the complete guideline; as well as 86.9% of those between 70 and 79 years old. From the group of 60 a 69, has a dose on 88,6%, but with the two just over 12.8%.
These days the communities are rescheduling appointments to continue the campaign among essential professionals under 60 years who were vaccinated with a first dose of AstraZeneca, and that now they can choose to receive the second one from Pfizer, or repeat with the Oxford preparation, although they must sign a consent in the case of opting for the same vaccine.
In this sense, Public Health Commission has insisted that the recommendation For people under 60 years of age vaccinated with the first dose of AstraZeneca, the second dose is with Pfizer. “Only in the case of rejecting this vaccine, it is considered exceptionally to be vaccinated with AstraZeneca after signing the corresponding informed consent,” Health has stressed.
It should be remembered that the companies Pfizer and BioNTech, developers of the Pfizer, have already presented to the European Medicines Agency (EMA) the dossier for the authorization of its vaccine (‘Comirnaty’) for use in the age group between 12 and 15 years old.
Once authorized, Health will propose to vaccinate minors from 12 years of age (year of birth 2009 or earlier) with conditions of very high risk or in situation of great dependency and those in centers for people with intellectual disability, supervised centers and special education centers.
The same path leads the vaccine Modern, which this Tuesday announced that its vaccine against covid-19 is safe and effective for adolescents between 12 and 17 years old, which brings the possibility of it being the second approved in the US for this age group. In addition, the American laboratory is going to present early June a demand for authorization to the European Medicines Agency (EMA) so that its vaccine can be used for adolescents aged 12 to 17 years.